SAN DIEGO--(BUSINESS WIRE)--Results of a major health economics study recently published in the Journal of Medical Economics found that use of bioTheranostics’ CancerTYPE ID® molecular test is a cost-effective approach to standardizing diagnostic methods for patients with metastatic tumors of uncertain origin while improving patient care.
The study—the first of its kind to examine the implications of molecular classification in standardizing the diagnostic process for metastatic cancer—was designed to estimate the clinical and economic tradeoffs of using CancerTYPE ID to aid in identifying the primary site of difficult-to-diagnose metastatic cancers and to explore whether the gene assay could be used to standardize the diagnostic process and costs for clinicians, payers, and patients.
Help employers find you! Check out all the jobs and post your resume.
